SCHOTT Pharma AG & Co. KGaA · ISIN: DE000A3ENQ51 · EQS - Company News

SCHOTT Pharma confirms outlook for FY 24 based on Q2 results; FY 25 impacted by slower growth from syringes

SCHOTT Pharma confirms outlook for FY 24 based on Q2 results; FY 25 impacted by slower growth from syringes H1 24 revenues up 9% yoy at constant currencies to EUR 489m; EBITDA margin of 27.4% at constant currencies FY 25 revenue growth projections impacted by lower demand for syringes from one customer Mid-term outlook confirmed Full set of Q2/H1 24 financial results to be published on June 27, 2024 SCHOTT Pharma, a pioneer in pharma drug containment solutions and delivery systems, continue...

XETR:1SXP Price indication powered by TradingView

About the publication

Corporate Insights - Short Sales, Director's Dealings, Sentiment Indicators - THE info hub for the informed investor

Smart tools for smart investors can be found in our Tools section

Corporate News SCHOTT Pharma AG & Co. KGaA

In this overview you can view company news in the chronological order of publication. The source information comes from EQS News, the leading European news distributor. The most recent news item is listed first.
Back to Corporate News Overview
This might be interesting for you as well
Analyst Ratings (0)
Directors Dealings (7)
Short Selling (DE) (1)
Short Selling (UK) (0)
14 May 2024 06:19PM
SCHOTT Pharma confirms outlook for FY 24 based on Q2 results; FY 25 impacted by slower growth from syringes
DE000A3ENQ51
SCHOTT Pharma confirms outlook for FY 24 based on Q2 results; FY 25 impacted by slower growth from syringes H1 24 revenues up 9% yoy at constant currencies to EUR 489m; EBITDA margin of 27.4% at constant currencies FY 25 revenue growth projections impacted by lower demand for syringes from one customer Mid-term outlook confirmed Full set of Q2...
SCHOTT Pharma AG & Co. KGaA
About the publication
14 May 2024 06:03PM
SCHOTT Pharma see FY 25 impacted by slower growth from syringes
DE000A3ENQ51
SCHOTT Pharma see FY 25 impacted by slower growth from syringes For its fiscal year 2024/2025, beginning 1st October 2024, the company is forecasting a revenue growth in a high single-digit to a low double-digit percentage range, which deviates from the current market consensus. Due to the revenue growth that is lower than previously expected, the...
SCHOTT Pharma AG & Co. KGaA
About the publication
18 March 2024 06:40PM
SCHOTT Pharma to Expand in the U.S. with New Prefillable Syringe Manufacturing Facility
DE000A3ENQ51
SCHOTT Pharma to Expand in the U.S. with New Prefillable Syringe Manufacturing Facility in Wilson, North Carolina 18 March 2024, Mainz, Germany With $371 million investment, new site to add over 400 jobs to the region First U.S. manufacturing facility to fill demand for domestic supply of glass and polymer prefillable syringes that deliver mRNA, G...
SCHOTT Pharma AG & Co. KGaA
About the publication
14 March 2024 04:26PM
Shareholders approve all items on the agenda
DE000A3ENQ51
Successful 2024 Annual General Meeting of SCHOTT Pharma: Shareholders approve all items on the agenda SCHOTT Pharma's first Annual General Meeting was held virtually on March 14, 2024 Shareholders approved all items on the agenda  SCHOTT Pharma, a pioneer in pharma drug containment solutions and delivery systems, held its first Annual General M...
SCHOTT Pharma AG & Co. KGaA
About the publication
29 February 2024 07:00AM
SCHOTT Pharma reports good start into fiscal year 2024
DE000A3ENQ51
SCHOTT Pharma reports good start into fiscal year 2024 Q1 2024 revenues of EUR 232m; increase of 8% yoy at constant currencies Q1 2024 EBITDA margin of 27.9% at constant currencies Share of strong-margin high-value solutions (HVS) further increased to 53% Guidance for fiscal year 2024 confirmed SCHOTT Pharma, a pioneer in pharma drug containmen...
SCHOTT Pharma AG & Co. KGaA
About the publication
26 January 2024 07:00AM
SCHOTT Pharma delivers on 2023 targets and continues profitable growth trajectory
DE000A3ENQ51
SCHOTT Pharma delivers on 2023 targets and continues profitable growth trajectory FY 2023: Revenues up 9% yoy to EUR 899m, EBITDA increase of 9% to EUR 239m, maintaining high EBITDA margin of 26.6% Strategic shift towards strong-margin high-value solutions (HVS) further accelerated, representing 48% of full year revenues For FY 2024, SCHOTT Pha...
SCHOTT Pharma AG & Co. KGaA
About the publication
19 December 2023 09:30AM
SCHOTT Pharma delivers right after IPO with strong profitable growth for the full year, at the upper end of its guidance
DE000A3ENQ51
SCHOTT Pharma delivers right after IPO with strong profitable growth for the full year, at the upper end of its guidance Successful fiscal year 2023, with a year-on-year increase in revenues of 9% to EUR 899m supported by increased share of revenue from strong-margin high-value solutions Strong EBITDA increase of 9% to EUR 239m leads to an EBITDA...
SCHOTT Pharma AG & Co. KGaA
About the publication
06 December 2023 08:00AM
Hello SDAX! SCHOTT Pharma reaches next milestone as a publicly listed company
DE000A3ENQ51
Hello SDAX! SCHOTT Pharma reaches next milestone as a publicly listed company SCHOTT Pharma to join the 160 most important shares listed on the Frankfurt stock exchange as of December 15, 2023 SDAX inclusion underlines company value, business model and strategy   The shares of SCHOTT Pharma AG & Co. KGaA (the “Company”; WKN A3ENQ5, ISIN DE0...
SCHOTT Pharma AG & Co. KGaA
About the publication
06 October 2023 06:10PM
Early termination of stabilization period and full exercise of the Greenshoe Option
DE000A3ENQ51
  NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, JAPAN OR SOUTH AFRICA OR ANY OTHER JURISDICTION IN WHICH SUCH DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. SCHOTT Pharma IPO: Early termination of stabilization period and full exercise of the Greenshoe Optio...
SCHOTT Pharma AG & Co. KGaA
About the publication
06 October 2023 08:00AM
Exercise of the Greenshoe Option and Post-stabilisation Period Announcement
DE000A3ENQ51
  6 October 2023   Not for distribution, directly or indirectly, in or into the United States or any jurisdiction in which such distribution would be unlawful.   SCHOTT Pharma AG & Co. KGaA   Exercise of the Greenshoe Option and Post-stabilisation Period Announcement   Further to the pre-stabilisation period announcement dated 27 Septe...
Bank of America Securities Europe SA
About the publication
27 September 2023 09:49PM
Final offer price set at EUR 27.00 per share
DE000A3ENQ51
  NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, JAPAN OR SOUTH AFRICA OR ANY OTHER JURISDICTION IN WHICH SUCH DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. SCHOTT Pharma IPO: Final offer price set at EUR 27.00 per share Placement of 34,641,362 shares (incl...
SCHOTT Pharma AG & Co. KGaA
About the publication
27 September 2023 09:39PM
Final offer price for shares in SCHOTT Pharma set at EUR 27.00 per share
DE000A3ENQ51
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, JAPAN OR SOUTH AFRICA OR ANY OTHER JURISDICTION IN WHICH SUCH DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL.   Final offer price for shares in SCHOTT Pharma set at EUR 27.00 per share The final offer price for t...
SCHOTT Pharma AG & Co. KGaA
About the publication
More SCHOTT Pharma AG & Co. KGaA related information
Type Total Last Made by Go to
Corporate Research 0 - - Corporate Research
Directors Dealings 7 5th March 2024 Schulte, Dr. Jens DD
Short Seller (DE) 1 10th June 2024 Millennium International Management LP SSR (DE)
Short Seller (UK) 0 - - SSR (UK)
Disclaimer:

The combination of information with graphic elements makes an important contribution to visual orientation and navigation through complex factual topics. Essential content features can be perceived, grasped and contextually processed much faster. 
The figurative marks, logos and other graphic and textual elements used on this website are for illustrative purposes only. All rights to the aforementioned elements are held by their respective owners. They are used without the intention of copyright infringement or intellectual property infringement.

If you believe that copyrights or intellectual property have been infringed by the choice of illustration, please contact us immediately to clarify the issue.

v.07062023 EN